Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M. Amalric

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Neuroscience|October 26, 2005
The metabotropic glutamate receptor subtype 5 antagonist MPEP and the Na+ channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesionsC Risterucci, R Coccurello, M Banasr, et al.
Psychopharmacology|January 1, 1987
Rewarding properties of beta-endorphin as measured by conditioned place preferenceM Amalric, E J Cline, J L Martinez, et al.
Psychopharmacology|August 6, 2000
Differential effects of dopamine receptor subtype blockade on performance of rats in a reaction-time paradigmA D Smith, D L Smith, M J Zigmond, et al.
Neurobiology of Disease|January 17, 2012
Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivityS Lopez, L Jouve, N Turle-Lorenzo, et al.
Journal of Neurobiology|July 21, 1999
Down-regulation of striatin, a neuronal calmodulin-binding protein, impairs rat locomotor activityM Bartoli, J P Ternaux, C Forni, et al.
Brain Research|October 29, 1986
The role of the nucleus raphe pontis and the caudate nucleus in alfentanil rigidity in the ratT A Blasco, D Lee, M Amalric, et al.
Brain Research|October 29, 1986
'Catatonia' produced by alfentanil is reversed by methylnaloxonium microinjections into the brainM Amalric, T A Blasco, N T Smith, et al.
Neuropharmacology|June 6, 2012
Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's diseaseM Amalric, S Lopez, C Goudet, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Neuroscience|October 26, 2005
The metabotropic glutamate receptor subtype 5 antagonist MPEP and the Na+ channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesionsC Risterucci, R Coccurello, M Banasr, et al.
Psychopharmacology|January 1, 1987
Rewarding properties of beta-endorphin as measured by conditioned place preferenceM Amalric, E J Cline, J L Martinez, et al.
Psychopharmacology|August 6, 2000
Differential effects of dopamine receptor subtype blockade on performance of rats in a reaction-time paradigmA D Smith, D L Smith, M J Zigmond, et al.
Neurobiology of Disease|January 17, 2012
Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivityS Lopez, L Jouve, N Turle-Lorenzo, et al.
Journal of Neurobiology|July 21, 1999
Down-regulation of striatin, a neuronal calmodulin-binding protein, impairs rat locomotor activityM Bartoli, J P Ternaux, C Forni, et al.
Brain Research|October 29, 1986
The role of the nucleus raphe pontis and the caudate nucleus in alfentanil rigidity in the ratT A Blasco, D Lee, M Amalric, et al.
Brain Research|October 29, 1986
'Catatonia' produced by alfentanil is reversed by methylnaloxonium microinjections into the brainM Amalric, T A Blasco, N T Smith, et al.
Neuropharmacology|June 6, 2012
Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's diseaseM Amalric, S Lopez, C Goudet, et al.
Pageof 5